Get the Stockscreener App
22.23
7.37%
-1.77
Instil Bio Inc stock is traded at $22.23, with a volume of 336.24K.
It is down -7.37% in the last 24 hours and up +1.37% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$24.00
Open:
$23.63
24h Volume:
336.24K
Relative Volume:
1.09
Market Cap:
$145.80M
Revenue:
-
Net Income/Loss:
$-74.14M
P/E Ratio:
-1.9517
EPS:
-11.39
Net Cash Flow:
$-65.70M
1W Performance:
-29.85%
1M Performance:
+1.37%
6M Performance:
-0.13%
1Y Performance:
+78.55%
1-Day Range:
$22.22
$24.44
1-Week Range:
$22.22
$32.40
52-Week Range:
$9.85
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
22.23 | 157.44M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - The Globe and Mail
What MACD and RSI say about Instil Bio Inc.Historical Stock Summary and ROI Review - Newser
What are the technical indicators suggesting about Instil Bio Inc.Entry Signal Outlook For Every Investor - jammulinksnews.com
Chart based analysis of Instil Bio Inc. trendsShort-Term Market Movement Forecast Report - Newser
Why Instil Bio Inc. is moving todayCommunity Picked Stocks with Trade Insights - Newser
What makes Instil Bio Inc. stock price move sharplyEarnings Report Alerts With Proven Results - jammulinksnews.com
Instil Bio Inc. Earnings Report Breakdown: What Investors Should KnowFree Watchlist for Low Risk High Return - Newser
Will Instil Bio Inc. rebound enough to break evenAnnual Market Behavior and Sector Summary - Newser
Sectors Driving Future Growth for Instil Bio Inc. StockFree Step-by-Step Stock Investment Guide - Newser
Instil Bio Reports Promising Phase 2 Study Results - TipRanks
ImmuneOnco, Instil Bio’s PD-L1xVEGF posts encouraging mid-stage data - Endpoints News
Candlestick signals on Instil Bio Inc. stock todayHigh Return Stock Focus With Safety Emphasized - metal.it
Instil Bio stock rises after positive data for cancer therapy in China - Investing.com Canada
Instil Bio stock rises after positive data for cancer therapy in China By Investing.com - Investing.com South Africa
What institutional investors are buying Instil Bio Inc. stockAI Powered Ideas With High Returns - jammulinksnews.com
ImmuneOnco Announced Preliminary Safety & Efficacy Data - GlobeNewswire
What high frequency data says about Instil Bio Inc.High Probability Trade Plan with Indicators - Newser
Comparing Instil Bio Inc. in custom built stock radarsFree Breakout Confirmation With Entry Tracker - Newser
How to interpret RSI for Instil Bio Inc. stockHigh Yield Watchlist with Filtered Picks - Newser
Will Instil Bio Inc. stock benefit from interest rate changesStrong Buy Opportunity with Volume Support - Newser
Technical Models Suggest Instil Bio Inc. May Rebound SoonAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Should I hold or sell Instil Bio Inc. stock in 2025Breakthrough profit margins - jammulinksnews.com
How volatile is Instil Bio Inc. stock compared to the marketDouble-digit growth - jammulinksnews.com
How does Instil Bio Inc. compare to its industry peersAchieve rapid financial growth with expert help - jammulinksnews.com
How to interpret RSI for Instil Bio Inc. stock High Return Idea With Technical Filter - Newser
Candlestick signals on Instil Bio Inc. stock today Free Wealth Building Stock Market Ideas - Newser
What are Instil Bio Inc. company’s key revenue driversUnlock daily market insights for better trades - jammulinksnews.com
What is the risk reward ratio of investing in Instil Bio Inc. stockHigh-margin investment plays - jammulinksnews.com
Instil Bio Inc. Company’s Quarterly Earnings Growth: What the Numbers SayWatchlist Winner Update - metal.it
How does Instil Bio Inc. generate profit in a changing economyAchieve rapid portfolio appreciation today - jammulinksnews.com
Is Instil Bio Inc. stock overvalued or undervaluedFree Stock Movement Tracking - jammulinksnews.com
How strong is Instil Bio Inc. company’s balance sheetUnlock daily market insights for better decisions - jammulinksnews.com
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):